From professional translators, enterprises, web pages and freely available translation repositories.
concept paper on the development of a cpmp points to consider on allergic rhino- conjuctivitis.
concept paper on the development of a cpmp points to consider on allergic rhino-conjuctivitis.
aerius var effektivt til at lindre generne ved sæsonbetinget allergisk rhinitis, vist ved den totale score i rhino-konjunktivitis livskvalitetsspørgeskemaet.
aerius was effective in alleviating the burden of seasonal allergic rhinitis as shown by the total score of the rhino-conjunctivitis quality of life questionnaire.
aerius-tabletter lindrede effektivt generne ved sæsonbetonet allergisk rhinitis, vist ved den totale score i rhino-konjunktivitis livskvalitetsspørgeskemaet.
aerius tablets were effective in alleviating the burden of seasonal allergic rhinitis as shown by the total score of the rhino-conjunctivitis quality of life questionnaire.
side 41/59points to consider on biostatistical/methodological issues arising from cpmp discussion on licensing applications:choice of non-inferiority margin points to consider on biostatistical/methodological issues arising from cpmp discussion on licensing applications:adjustment for baseline covariates points to consider on the use of statistical methods for flexible design and analysis of confirmatory clinical trials points to consider on clinical pharmacokinetic investigation of the pharmacokinetics of peptides and proteins note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with impaired renal function points to consider on the evaluation of the pharmacokinetics of medicinal products in the paediatric population note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with hepatic impairment note for guidance on clinical investigation of medicinal products for the treatment of psoriasis points to consider on allergic rhino-conjuctivitis addendum to the note for guidance on modified release oral and transdermal dosage forms:
note for guidance on the evaluation of medicinal products forthe treatment of dyslipoproteinaemianote for guidance on clinical investigation of steroid contraceptives in women revision of note for guidance on evaluation of new anti-bacterial medicinal products (cpmp/ewp/558/95) and note for guidance on the pharmacodynamic section of the summary of product characteristics for antibacterial medicinal productspoints to consider on biostatistical/methodological issues arisingfrom cpmp discussion on licensing applications:choice of non-inferiority marginpoints to consider on biostatistical/methodological issues arising from cpmp discussion on licensing applications:adjustment forbaseline covariatespoints to consider on the use of statistical methods for flexibledesign and analysis of confirmatory clinical trialspoints to consider on clinical pharmacokinetic investigation of the pharmacokinetics of peptides and proteinsnote for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with impaired renal functionpoints to consider on the evaluation of the pharmacokinetics of medicinal products in the paediatric population note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with hepatic impairment note for guidance on clinical investigation of medicinal products for the treatment of psoriasis points to consider on allergic rhino-conjuctivitis addendum to the note for guidance on modified release oral and transdermal dosage forms:
